ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

ViiV Healthcare is committed to ensuring timely public access for APRETUDE to help reduce the risk of sexually acquired HIV-1 infection and make progress towards global targets of ending HIV by ...

ViiV Healthcare understands this push-and-pull dynamic all too well and sought out to do something about it. “Both sides are waiting for the other person to initiate and take the lead in those deeper ...

"We're kind of in the epicenter of where HIV is hitting hard, and a lot of people don't know it," Bithiah Lafontant, ViiV Director of Corporate Communications, told HBCU Legends. "We really want ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

LONDON, October 07, 2024--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the company’s ...

As HIV/AIDS continues to disproportionately affect Southerners in general and Blacks in particular, GSK’s ViiV Healthcare, the only pharma firm solely focused on that medical area, tackles the ...

Additional key abstracts from ViiV Healthcare’s industry-leading, long-acting pipeline and portfolio include data introducing a third-generation integrase strand transfer inhibitor (INSTI) with ...

Other key data to be presented from ViiV Healthcare’s innovative pipeline and portfolio include the exploration of different mechanisms of action through broadly neutralising antibodies as well as ...

Among the companies that have ventured the most into this audio medium is GSK’s ViiV Healthcare, which focuses on research and development of HIV/AIDS treatments. Launched in 2020, the company’s Being ...

LONDON, Feb 22 (Reuters) - British drugmaker GSK's (GSK.L), opens new tab HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective ...

GSK lifts growth target for HIV business on demand for long-acting drug GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long ...